Sobi announced an acquisition agreement to buy Arthrosi Therapeutics, paying $950 million upfront with up to $550 million in contingent milestones. The deal brings a Phase 3 gout candidate into Sobi’s portfolio and accelerates its rare-disease and specialty inflammation strategy. The Swedish drugmaker said the deal transfers Arthrosi’s clinical program and associated development assets; milestone payments hinge on late‑stage trial readouts and regulatory progress. Investors and competitors will watch how Sobi integrates the program and funds Phase 3 completion. The acquisition underscores ongoing consolidation among specialty biotechs developing targeted therapies for inflammatory metabolic diseases. Potential regulatory timelines and the Phase 3 design will determine near-term value realization for Sobi and shareholders.